A phase II study of fenretinide in patients with hormone refractory prostate cancer: A trial of the Cancer Therapeutics Research Group

Cancer Chemotherapy and Pharmacology

Volumn 66, Issue 5, 2010, Pages 845-850

  Moore, M M ^a   Stockler, M ^b   Lim, R ^c   Mok, T S K ^d   Millward, M ^e   Boyer, M J ^a  

^a SYDNEY CANCER CENTRE   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^d CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^e SIR CHARLES GAIRDNER HOSPITAL   (Australia)

Author keywords

Fenretinide; Hormone refractory; Prostate cancer

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; CYPROTERONE; FENRETINIDE; FLUTAMIDE; NILUTAMIDE; PROSTATE SPECIFIC ANTIGEN;

ABDOMINAL DISCOMFORT; ADULT; AGED; ANOREXIA; ARTHRALGIA; ARTICLE; BACKACHE; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RESISTANCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPNEA; EDEMA; HOT FLUSH; HUMAN; HYPERTRIGLYCERIDEMIA; LETHARGY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NIGHT BLINDNESS; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PRURITUS; SOFT TISSUE METASTASIS; TREATMENT RESPONSE; VOMITING; XEROSTOMIA;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; FENRETINIDE; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TREATMENT FAILURE;

EID: 77956231243     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-1228-x     Document Type: Article

References (25)

1. Ferlay JBF, Pisani P, Parkin DM (2001) GLOBOCAN 2000: cancer incidence, mortality and prevalence worldwide. IARC Press, Lyon
2. PW Kantoff, et al. 1999 Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study [see comment] J Clin Oncol 17 8 2506 2513 1:CAS:528:DyaK1MXltlyltL8%3D 10561316
3. IF Tannock, et al. 1996 Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points [see comment] J Clin Oncol 14 6 1756 1764 1:CAS:528:DyaK28XjslOrsr8%3D 8656243
4. IF Tannock, et al. 2004 Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer [see comment] N Engl J Med 351 15 1502 1512 10.1056/NEJMoa040720 1:CAS:528:DC%2BD2cXot1Kmu7s%3D 15470213
5. SJ Martin JG Bradley TG Cotter 1990 HL-60 cells induced to differentiate towards neutrophils subsequently die via apoptosis Clin Exp Immunol 79 3 448 453 10.1111/j.1365-2249.1990.tb08110.x 1:STN:280:DyaK3c3gtVWqug%3D%3D 2317949
6. MS Tallman PH Wiernik 1992 Retinoids in cancer treatment J Clin Pharmacol 32 10 868 888 1:CAS:528:DyaK2cXjtFCqu78%3D 1447394
7. LN Chan, et al. 1997 N-(4-hydroxyphenyl)retinamide induces apoptosis in T lymphoma and T lymphoblastoid leukemia cells Leuk Lymphoma 25 3-4 271 280 1:CAS:528:DyaK1MXislCju74%3D 9168437
8. KM Roberson, et al. 1997 Fenretinide: induction of apoptosis and endogenous transforming growth factor beta in PC-3 prostate cancer cells Cell Growth Differ 8 1 101 111 1:CAS:528:DyaK2sXltVWqtA%3D%3D 8993839
9. AL Sabichi, et al. 1998 Retinoic acid receptor beta expression and growth inhibition of gynecologic cancer cells by the synthetic retinoid N-(4-hydroxyphenyl) retinamide J Natl Cancer Inst 90 8 597 605 10.1093/jnci/90.8.597 1:CAS:528:DyaK1cXivFGis74%3D 9554442
10. RC Moon, et al. 1992 Chemoprevention of MNU-induced mammary tumors in the mature rat by 4-HPR and tamoxifen Anticancer Res 12 4 1147 1153 1:CAS:528:DyaK2cXkt1Knsr4%3D 1386970
11. K Slawin, et al. 1993 Dietary fenretinide, a synthetic retinoid, decreases the tumor incidence and the tumor mass of ras + myc-induced carcinomas in the mouse prostate reconstitution model system Cancer Res 53 19 4461 4465 1:CAS:528:DyaK2cXit1E%3D 8402613
12. Y Zheng, et al. 1999 Effect of retinoids on AOM-induced colon cancer in rats: modulation of cell proliferation, apoptosis and aberrant crypt foci Carcinogenesis 20 2 255 260 10.1093/carcin/20.2.255 1:CAS:528:DyaK1MXhsFWgt7c%3D 10069462
13. MA Cobleigh, et al. 1993 Phase I/II trial of tamoxifen with or without fenretinide, an analog of vitamin A, in women with metastatic breast cancer J Clin Oncol 11 3 474 477 1:STN:280:DyaK3s7oslKrsg%3D%3D 8445423
14. Cobleigh MA, Gray R, Graham M (2000) Fenretinide versus placebo in the postmenopausal breast cancer patients receiving adjuvant tamoxifen. An Eastern Cooperative Oncology Group Phase III intergroup trial (EB193,INT-0151) 19 Abstract 328. In: Proc American society of clinical oncology
15. MR Modiano, et al. 1990 Phase II study of fenretinide (N-[4-hydroxyphenyl]retinamide) in advanced breast cancer and melanoma Invest New Drugs 8 3 317 319 10.1007/BF00171846 1:STN:280:DyaK3M7gslahsA%3D%3D 2148744
16. KJ Pienta, et al. 1997 Phase II chemoprevention trial of oral fenretinide in patients at risk for adenocarcinoma of the prostate Am J Clin Oncol 20 1 36 39 10.1097/00000421-199702000-00008 1:STN:280:DyaK2s7nt1ajsw%3D%3D 9020285
17. D Urban, et al. 1999 Evaluation of biomarker modulation by fenretinide in prostate cancer patients Eur Urol 35 5-6 429 438 10.1159/000019875 1:CAS:528:DyaK1MXjvFOktrs%3D 10325501
18. U Veronesi, et al. 1999 Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. [see comment] J Natl Cancer Inst 91 21 1847 1856 10.1093/jnci/91.21.1847 1:CAS:528:DyaK1MXns1Clsbk%3D 10547391
19. P Therasse, et al. 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada [see comment] J Natl Cancer Inst 92 3 205 216 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D 10655437
20. VK Puduvalli, et al. 2004 Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study J Clin Oncol 22 21 4282 4289 10.1200/JCO.2004.09.096 1:CAS:528: DC%2BD2cXhtVKju7fM 15514370
21. U Vaishampayan, et al. 2005 Phase II trial of fenretinide in advanced renal carcinoma Invest New Drugs 23 2 179 185 10.1007/s10637-005-5864-7 1:CAS:528:DC%2BD2MXhslyruro%3D 15744595
22. AL Sabichi, et al. 2008 Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer [see comment] Clin Cancer Res 14 1 224 229 10.1158/1078-0432.CCR-07-0733 1:CAS:528:DC%2BD1cXoslGk 18172274
23. U Veronesi, et al. 2006 Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer [see comment] Ann Oncol 17 7 1065 1071 10.1093/annonc/mdl047 1:STN:280:DC%2BD28zotVarsQ%3D%3D 16675486
24. A Kokate X Li B Jasti 2007 Transport of a novel anti-cancer agent, fenretinide across Caco-2 monolayers Invest New Drugs 25 3 197 203 10.1007/s10637-006-9026-3 1:CAS:528:DC%2BD2sXltlartrg%3D 17146731
25. T Okuda, et al. 2009 Enhanced in vivo antitumor efficacy of fenretinide encapsulated in polymeric micelles Int J Pharm 373 1-2 100 106 10.1016/j.ijpharm.2009.01.019 1:CAS:528:DC%2BD1MXltlSjsLo%3D 19429294